Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data

Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data

Secukinumab, a selective interleukin (IL)-17A inhibitor, is approved for use in adult and paediatric psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis. The aim of this study was to report the long-term safety of secukinumab in pooled data from 28 cli...

Descripció completa

Dades bibliogràfiques
Autors principals:	Alice B. Gottlieb, Atul Deodhar, Iain B. Mcinnes, Xenofon Baraliakos, Kristian Reich, Stefan Schreiber, Weibin Bao, Kwaku Marfo, Hanno B. Richards, Luminita Pricop, Abhijit Shete, Vivek Trivedi, Deborah Keefe, Charis C. Papavassilis, Piotr Jagiello, Philemon Papanastasiou, Philip J. Mease, Mark Lebwohl
Format:	Article
Idioma:	English
Publicat:	Medical Journals Sweden 2022-04-01
Col·lecció:	Acta Dermato-Venereologica
Matèries:	Ankylosing spondylitis biologics interleukin psoriasis psoriatic arthritis safety
Accés en línia:	https://medicaljournalssweden.se/actadv/article/view/563

Ítems similars

Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study
per: Iain B. McInnes, et al.
Publicat: (2018-06-01)

Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)
per: Peter Nash, et al.
Publicat: (2018-03-01)

Efficacy and Safety of Secukinumab in US Patients with Psoriatic Arthritis: A Subgroup Analysis of the Phase 3 FUTURE Studies
per: Alan J. Kivitz, et al.
Publicat: (2024-04-01)

Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies
per: Laura C. Coates, et al.
Publicat: (2019-12-01)

Secukinumab for ankylosing spondylitis and psoriatic arthritis
per: Lubrano E, et al.
Publicat: (2016-10-01)

Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study
per: Alan J. Kivitz, et al.
Publicat: (2019-06-01)

Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study
per: Philip J. Mease, et al.
Publicat: (2023-10-01)

Persistence of secukinumab in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis
per: Elena Conesa-Nicolás, et al.
Publicat: (2021-01-01)

Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study
per: Sara Alonso, et al.
Publicat: (2021-05-01)

Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritis
per: Philip Mease, et al.
Publicat: (2022-12-01)

Experience in using secukinumab in patients with axial psoriatic arthritis
per: E. E. Gubar, et al.
Publicat: (2020-11-01)

Secukinumab for Psoriasis in Obese Patients: Minireview and Clinical Experience
per: Rossana Tiberio, et al.
Publicat: (2019-09-01)

Short-term Efficacy and Safety of Secukinumab in Pakistani Patients with Ankylosing Spondylitis and Psoriatic Arthritis
per: Sumera Ghani, et al.
Publicat: (2023-06-01)

Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data
per: A. Deodhar, et al.
Publicat: (2019-05-01)

Secukinumab in refractory non-infectious anterior uveitis
per: Otto M. Olivas-Vergara, et al.
Publicat: (2025-02-01)

Secukinumab retention rate is greater in patients with psoriatic arthritis presenting with axial involvement
per: G. Adami, et al.
Publicat: (2023-05-01)

Effects of secukinumab on serum adipocytokines: preliminary data
per: A. Fassio, et al.
Publicat: (2017-09-01)

Use of the interleukin-17A inhibitor secukinumab in psoriatic arthritis: a subanalysis of the Russian population in the international randomized clinical trials FUTURE 1 and FUTURE 2
per: T. V. Korotaeva, et al.
Publicat: (2017-04-01)

Experience of using secukinumab in the treatmentof patients with psoriasis
per: N. V. Zilberberg, et al.
Publicat: (2021-11-01)

Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial
per: Dafna D. Gladman, et al.
Publicat: (2022-09-01)

Cutaneous Vasculitis with Gut Involvement During Secukinumab Treatment for Psoriatic Arthritis
per: Clara Chelli, et al.
Publicat: (2020-03-01)

Characteristics of Patients with Psoriatic Arthritis Receiving Secukinumab and Reasons for Initiation: A US Retrospective Medical Chart Review
per: Prashanth Sunkureddi, et al.
Publicat: (2019-01-01)

Description of the Clinical Case of Adalimumab and Secukinumab Therapy of a Patient with Psoriatic Arthritis
per: V. V. Didenko, et al.
Publicat: (2021-05-01)

SUCCESSFUL USE OF AN INTERLEUKIN 17 INHIBITOR (SECUKINUMAB) IN THE TREATMENT OF ISOLATED DESTRUCTIVE ENTHESITIS IN PSORIATIC ARTHRITIS
per: E. E. Gubar, et al.
Publicat: (2018-11-01)

Real-world effectiveness and persistence of secukinumab in the treatment of patients with psoriatic arthritis
per: Juan José Alegre-Sancho, et al.
Publicat: (2023-11-01)

Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials
per: Rui Sun, et al.
Publicat: (2024-03-01)

Real-Life Data of Secukinumab in Patients with Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis: Patient Baseline Characteristics Data from the PROMPT Study
per: Ploysyne Rattanakaemakorn, et al.
Publicat: (2024-11-01)

Guselkumab in Biologic-Naïve Patients with Active Psoriatic Arthritis in Russia: A Post Hoc Analysis of the DISCOVER-1 and -2 Randomized Clinical Trials
per: Philip Mease, et al.
Publicat: (2024-09-01)

Real-world clinical experience with secukinumab in psoriatic arthritis: an observational study and a literature review
per: Eleonora Celletti, et al.
Publicat: (2025-01-01)

Secukinumab: A safe option to treat psoriasis and psoriatic arthritis in the presence of interstitial lung disease
per: Raja Natarajan
Publicat: (2019-01-01)

Efficacy and safety of secukinumab in patients with psoriatic arthritis: A meta-analysis of different dosing regimens
per: Kai-Lin Zhang, et al.
Publicat: (2021-10-01)

Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative
per: Colombo GL, et al.
Publicat: (2018-08-01)

Effectiveness of secukinumab in patients with psoriasis and psoriatic arthritis in a Saudi real-world setting
per: Ibrahim A. Al-Homood, et al.
Publicat: (2024-04-01)

Incidence of Uveitis in Secukinumab‐treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies
per: Atul A. Deodhar, et al.
Publicat: (2020-05-01)

Interleukin 17A inhibitor secukinumab in the treatment of patients with psoriatic arthritis
per: N. A. Shostak, et al.
Publicat: (2022-10-01)

Secukinumab in axial spondyloarthritis: a narrative review of clinical evidence
per: Jürgen Braun, et al.
Publicat: (2021-08-01)

Effectiveness and safety of secukinumab in axial spondyloarthritis and psoriatic arthritis: A retrospective analysis of its real-world usage from India
per: Sham Santhanam, et al.
Publicat: (2020-01-01)

Depressive symptoms are associated with fatigue, poorer functional status and less engagement in sports in axSpA and PsA: an analysis from the RABBIT-SpA cohort
per: Andreas Reich, et al.
Publicat: (2023-08-01)

Performance of standardized patient reported outcomes developed for spondyloarthritis in primary and concomitant forms of fibromyalgia
per: Styliani Tsiami, et al.
Publicat: (2024-07-01)

A Machine Learning Approach to Predict Remission in Patients With Psoriatic Arthritis on Treatment With Secukinumab
per: Vincenzo Venerito, et al.
Publicat: (2022-06-01)